Clinical Research Directory

Inclusion Criteria: * Documented AF * CHA2DS2-VASc score ≥ 4 and history of ischemic stroke (including TIA with positive neuro-imaging) * No contra-indication for patient to receive an OAC, either vitamin K antagonist (VKA) or novel oral anticoagulant (NOAC) for the duration of the study * Age \> 50 years * Maximal (systolic) CCA diameter range: ≥ 4.8mm and ≤ 9.8mm * CCA accessibility: up to 40mm from skin to CCA center, safe approach * Implantation segment free of atherosclerotic disease as determined by ultrasound imaging * Patient is able and willing to provide informed consent Exclusion Criteria: * Evidence of carotid stenosis \> 30% \[CCA, internal carotid artery (ICA), or external carotid artery (ECA)\] * Evidence of carotid dissection * Pre-existing stent(s) in CCA * Female who is pregnant or who is planning to become pregnant during the course of the study * Life expectancy of less than two years * Active systemic infection * Known sensitivity to nickel or titanium metals, or their alloys * Known hereditary or acquired coagulation disorders * Any planned surgical or endovascular treatment within 30 days after the implantation procedure * A co-morbid disease or condition that could confound the neurological and functional evaluations or compromise survival or ability to complete follow-up assessments\* Current use or a recent history of illicit drug(s) use or alcohol abuse (defined as regular or daily consumption of more than four alcoholic drinks per day) * Active participation in another investigational drug or device treatment study * Inability to complete all scheduled follow-up * Any other condition that in the opinion of the investigator may adversely affect the safety of the patient or would limit the patient's ability to complete the study * History of intracerebral hemorrhage (ICH) and/or hemorrhagic stroke * Event of stroke/TIA in the past 14 days